TMO Stock Price Today (July 2026) — Thermo Fisher Scientific Inc. Analysis & Key Metrics 2026-07-17
Thermo Fisher Scientific Inc. (TMO) is trading at $532.48, down 1.97% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $596.26 (12.0% upside).
- Volatility remains elevated (19.86% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (6.20% YoY) alongside significant competitive pressures.
TMO Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Thermo Fisher Scientific Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $226.35B
P/E Ratio
Forward P/E: 18.91
Revenue Growth
Year over Year
Analyst Target
+12.0% upside potential
Key Investor Questions About TMO
What investors need to know before buying
Based on current market data, TMO presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 63.37)
- Fundamentals say: Caution warranted (high leverage concerns)
TMO's growth trajectory depends on its ability to expand within the Diagnostics & Research sector while managing margin pressures.
- Future growth will depend on performance in core Diagnostics & Research operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for TMO investors include debt exposure and competitive dynamics in the Diagnostics & Research industry.
- $43.16B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Diagnostics & Research.
52-Week Trading Range
Over the past year, TMO stock traded between $403.36 and $643.99—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 19.86% annualized volatility and β=0.89, the stock exhibits moderate correlation to market moves—making TMO suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Abbott Just Showed Its Growth Engine Has More Than One Cylinder
The healthcare giant's stock jump was about more than an earnings beat, offering proof of a growth story broader and more resilient than you thought.
Can Abbott Stock Deliver on Its Second-Half Growth Promise?
This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.
Thermo Fisher Set to Report Q2 Earnings: What's in the Cards?
TMO readies for second-quarter 2026 earnings, with growth expected across key segments as bioproduction, clinical research and new launches support results.
Intuitive Surgical Pre-Q2 Analysis: Buy, Hold or Sell the Stock Now?
Intuitive Surgical heads into Q2 earnings with strong procedure momentum, da Vinci 5 adoption and expectations for another earnings beat despite margin pressures.
Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?
ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.
Alamar Hits A High Note On Alzheimer's Buzz
If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.
Thermo Fisher (TMO) Wins FBI Approval For Rapid DNA Tool In Crime Investigations
FBI approval of Thermo Fisher Scientific's RapidINTEL Plus Cartridge for forensic DNA profiling on the RapidHIT ID System. Rapid DNA workflows on RapidHIT ID can now generate profiles eligible for national CODIS database searches from qualifying crime scene samples. Approval enables law enforcement agencies to obtain actionable DNA intelligence within hours instead of longer traditional lab timelines. Regulatory milestone positions Thermo Fisher Scientific (NYSE:TMO) as a key player in next...
Is ICLR Stock a Value Trap or Turnaround After an Earnings Reset?
ICON trades below its five-year median, but weaker 2026 guidance, control issues and leverage keep the stock in wait-and-see territory.
ICON Stock Outlook 2026 as Margin Woes Meet a Stronger Backlog Base
ICON's stronger bookings and backlog hint at improving demand, but margin pressure, earnings declines and control remediation keep 2026 cautious.
Top 10 medtech deals in the first half of 2026
Boston Scientific, Medtronic and Stryker were among the companies to ink deals to move into markets that are expanding quickly.
Frequently Asked Questions
Common investor questions about Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. (TMO) is currently trading at $532.48. The RSI (14-day) is at 63.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $596.26 implies 12.0% upside from current levels. Volatility is low at 19.9% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Thermo Fisher Scientific Inc. (TMO): The trailing P/E ratio is 29.26, which is in line with broader market averages. The forward P/E is 18.91, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.65, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 3.81. Price-to-Sales is 4.38. Valuation should be compared to Diagnostics & Research industry peers for context, as different sectors trade at different multiples.
Based on 27 analysts covering TMO, the consensus price target is $596.26. This represents a 12.0% upside from the current price of $532.48. The range spans from a low target of $490.00 to a high target of $750.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Thermo Fisher Scientific Inc. (TMO) pays a dividend with a current yield of approximately 35.00%. The annualized dividend rate is $1.76 per share. The payout ratio is 9.7%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-06-15T00:00:00.000Z.
Key risks for Thermo Fisher Scientific Inc. (TMO) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Diagnostics & Research sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Thermo Fisher Scientific Inc.'s (TMO) current debt and financial health profile: Total debt stands at $43.16B. The debt-to-equity ratio is 82.90, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.53, indicating strong short-term liquidity. The quick ratio is 0.97. The company holds $3.26B in cash and equivalents. Free cash flow is positive at $5.52B, providing a cushion for debt servicing and shareholder returns.